China Has Nearly as Many Monoclonal Antibodies in Phase 3 Trials as the Rest of the World Combined
Number of mAbs per region group by most advanced development phase
Stacked column chart of late-stage clinical monoclonal antibody candidates by development phase — Phase 2 pivotal, Phase 2/3, and Phase 3 — where China contributes roughly half of all Phase 3 candidates globally.
